Published • loading... • Updated
Saptalis Launches Cyclosporine Ophthalmic Emulsion 0.05%; Expands Portfolio Across Multiple Therapeutic Areas
Summary by Eyewire+
2 Articles
2 Articles
Saptalis Launches Cyclosporine Ophthalmic Emulsion 0.05%; Expands Portfolio Across Multiple Therapeutic Areas
Saptalis Pharmaceuticals announced the commercial launch of cyclosporine ophthalmic emulsion 0.05%, a generic version of Restasis (Abbvie), for the treatment of dry eye disease. The preservative-free, single-use formulation, which is available in 30-count and 60-count single-use vials, is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjuncti…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
